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Acquired carbapenemases confer extensive antibiotic 
resistance to Enterobacteriaceae and represent a pub-
lic health threat. A novel acquired carbapenemase, 
New Delhi metallo-beta-lactamase 1 (NDM-1), has 
recently been described in the United Kingdom and 
Sweden, mostly in patients who had received care on 
the Indian subcontinent. We conducted a survey among 
29 European countries (the European Union Member 
States, Iceland and Norway) to gather information on 
the spread of NDM-1-producing Enterobacteriaceae 
in Europe, on public health responses and on avail-
able national guidance on detection, surveillance 
and control. A total of 77 cases were reported from 13 
countries from 2008 to 2010. Klebsiella pneumoniae 
was the most frequently reported species with 54%. 
Among 55 cases with recorded travel history, 31 had 
previously travelled or been admitted to a hospital in 
India or Pakistan and five had been hospitalised in 
the Balkan region. Possible nosocomial acquisition 
accounted for 13 of 77 cases. National guidance on 
NDM-1 detection was available in 14 countries and on 
NDM-1 control in 11 countries. In conclusion, NDM-1 is 
spreading across Europe, where it is frequently linked 
to a history of healthcare abroad, but also to emerg-
ing nosocomial transmission. National guidance in 
response to the threat of carbapenemase-producing 
Enterobacteriaceae is available in approximately half 
of the surveyed European countries. Surveillance of 
carbapenemase- producing Enterobacteriaceae must 
be enhanced in Europe and effective control measures 
identified and implemented.
Introduction
New Delhi metallo-beta-lactamase 1 (NDM-1) is a 
newly-described metallo-beta-lactamase (MBL), first 
identified in 2008 in single isolates of Klebsiella pneu-
moniae and Escherichia coli, both recovered from a 
patient repatriated to Sweden after treatment in a hos-
pital in New Delhi, India [1]. Like other acquired MBLs, 
NDM-1 hydrolyses all beta-lactam antibiotics except for 
aztreonam, which is usually inactivated by co-produced 
extended-spectrum or AmpC beta-lactamases. An 
association with other resistance mechanisms makes a 
majority of Enterobacteriaceae with blaNDM-1 extensively 
resistant to antibiotics and susceptible only to colistin 
and, less consistently, tigecycline [1,2]. 
Acquired carbapenemases are a large group of beta-
lactamases of high structural diversity that, in most 
instances, hydrolyse not only carbapenems, but also 
oxyimino-cephalosporins and cephamycins [3]. For 
over a decade, different types of acquired carbapen-
emases have gradually begun to appear in clinical iso-
lates of Enterobacteriaceae and other Gram-negative 
bacteria. In Europe, VIM-type MBLs and the so-
called K. pneumoniae carbapenemases (KPC) are the 
most frequently isolated carbapenemases, although 
K. pneumoniae producing the class D OXA-48 carbap-
enemase is prevalent in Turkey ([3,4]. Overall, car-
bapenem-resistant Enterobacteriaceae are still rare 
causes of human infections in most parts of Europe, 
except for Greece and Cyprus [3-5]. According to the 
2009 data from the European Antimicrobial Resistance 
Surveillance Network (EARS-Net, formerly EARSS) [5] 
the rates of carbapenem-resistance among invasive 
K. pneumoniae infections were: 43.5% in Greece, 17.0% 
in Cyprus, 1.3% in Italy, 1.2% in Belgium and below 1% 
in the other 23 reporting countries [5]. Despite these 
generally low rates, carbapenemase-producing strains 
of K. pneumoniae harbouring either blaVIM or blaKPC 
have been the cause of country-wide epidemics of 
healthcare-associated infections in Greece, Israel, the 
United States (US), several Latin American countries 
and China, and of local outbreaks in Poland and Italy 
[3,4,6]. These epidemic strains, plasmids, and trans-
posons bearing carbapenemases have been shown to 
spread when carried by patients who are transferred 
between hospitals [3,6]. Such introductions into 
healthcare systems across country borders have led to 
international epidemics by secondary local or regional 
transmission [1-3,6]. 
After the initial report of NDM-1 from Sweden in 2008 
[1], the Health Protection Agency (HPA) in the United 
Kingdom (UK), concerned over the rapid increase in the 
number of cases of human colonisation and infection 
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with NDM-1 and other carbapenemase-producing 
Enterobacteriaceae in hospitals across the country, 
issued a national alert in July 2009 [7]. Similarly to 
the first case of NDM-1 reported by Yong et al. [1], the 
majority of the patients with NDM-1-positive bacteria 
in the UK had a history of travel to India or Pakistan, 
where many of them had been hospitalised with vari-
ous indications, including elective surgery and renal 
dialysis [2,7]. 
These reports indicate that the majority of the bacteria 
carry blaNDM-1 on conjugative plasmids of variable size 
[1,2]. Among Enterobacteriaceae, E. coli and K. pneumo-
niae are the most frequent host species but NDM-1 has 
already been recorded in Klebsiella oxytoca, Citrobacter 
freundii, Enterobacter cloacae, Morganella morganii, 
Proteus spp. and Providencia spp. [1,2]. 
The worldwide spread of Enterobacteriaceae that carry 
carbapenemase-producing genes, including blaNDM-1, is 
a significant threat to human health: Firstly, the pro-
duction of carbapenemase, in association with other 
resistance determinants, confers extensive drug resist-
ance, leaving few or no therapeutic options. Secondly, 
the association with travel underscores the risk of 
healthcare in countries where antibiotic-resistant 
bacteria are endemic [2]. Lastly, studies of patients 
infected with Enterobacteriaceae producing KPC are at 
increased risk of complications and death [8,9].
On 23 August 2010, following publication of the UK 
cases [2], the French National Public Health Surveillance 
Institute (InVS) posted an alert on the European Early 
Warning and Response System (EWRS), to share with 
other European Union (EU) Member States information 
on two cases infected with NDM-1-producing bacte-
ria related to hospitalisation on the Indian subconti-
nent. On 27 August, the European Centre for Disease 
Prevention and Control (ECDC) produced and shared 
with the Commission and all EU Member States a threat 
assessment on “New Delhi metallo-beta-lactamase 
(NDM-1) carbapenemase-producing Enterobacteriaceae 
from the Indian subcontinent”, based on a prelimi-
nary review of all NDM-1-producing bacteria reported 
at that time in six EU member states (Belgium, France, 
Germany, the Netherlands, Sweden and the UK). The 
present study is an update of this initial assessment 
and describes the geographical distribution and epi-
demiological features of NDM-1-producing bacteria 
detected to date in the EU Member States, Iceland and 
Norway. It also reports on the availability of national 
guidance on detection, surveillance, notification and 
control of NDM-1- and other carbapenemase-producing 
Enterobacteriaceae in these countries.
Methods
We searched  the medical literature for articles on “New 
Delhi metallo-beta-lactamase” OR “NDM-1” published 
until 15 November 2010 to identify cases reported from 
Europe and also included relevant references provided 
by consulted experts. To expand this search beyond 
published cases, an electronic questionnaire sur-
vey was sent out on 20 September 2010 to the ECDC 
National Antimicrobial Resistance Focal Points and 
the European Antimicrobial Resistance Surveillance 
Network (EARS-Net) Contact Points from all EU Member 
States, Iceland and Norway. The purpose of this survey 
was to register, by country, all cases of infection with 
NDM-1-producing bacteria. An NDM-1 case was defined 
as a patient from whom one or more Enterobacteriaceae 
had been isolated that expressed the NDM-1 enzyme as 
confirmed by an expert laboratory. The survey also col-
lected the following clinical and microbiological data: 
the bacterial species producing the NDM-1 enzyme and 
the date of detection, the type of infection, the sex and 
age of the patient, the patient’s clinical status at hospi-
tal discharge or at the last follow-up, any recent travel 
history (within the 30 days before detection of NDM-
1) or contact with healthcare facilities abroad (also 
stating in which country), and any local transmission 
events with known contact with a travel-associated 
case. 
The questionnaire also included queries about whether 
there were published national guidelines, recommen-
dations or guidance documents addressing the follow-
ing issues in the context of carbapenemase-producing 
Enterobacteriaceae: methods of microbiological detec-
tion, referral of isolates to reference microbiology labo-
ratories, notification of public health authorities, and 
infection control measures to limit spread.
Results 
We identified 19 peer-reviewed publications on NDM-1 
enzyme [1,2,10-26], of which 12 reported primary data. 
NDM-1 cases reported from Europe (n=38) included 
two cases from Austria [20], two from Belgium [25], one 
from Denmark [23], one from France [26], two from the 
Netherlands [16,24], one from Sweden [1] and 29 from 
the UK [2]. Cases were also reported from Australia [18], 
Canada [19], Singapore [21] and the US [10]. Infections 
with NDM-1-producing Acinetobacter baumannii were 
reported from Germany, India and the UK [2,17,22]. 
Investigations showed that the NDM-1 enzyme was 
frequently detected among clinical Enterobacteriaceae 
isolates in Chennai, Haryana, Mumbai and other Indian 
cities [2,10].
All 29 questionnaires mailed to the countries were 
completed and returned. Table 1 summarises the epi-
demiological characteristics of the 77 patients with 
one or more isolates of Enterobacteriaceae with an 
NDM-1 enzyme (referred to as ‘NDM-1 cases’) reported 
in 13 European countries between 1 January 2008 and 
7 October 2010, grouped by country of diagnosis. The 
total number of cases increased by year from eight in 
2008, 30 in 2009 and 39 in the first nine months of 
2010.
Of the 77 cases reported in the questionnaires, 51 
originated from the UK. The patients’ age ranged from 
2 to 87 years and the male:female ratio was 0.62. 
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Species information was available for 57 isolates (from 
53 patients) producing an NDM-1 enzyme. They were 
distributed among six species: K. pneumoniae (n=31),
E. coli (n=16), Enterobacter spp. (n=4), C. freundii 
(n=3), M. morganii (n=2) and Proteus mirabilis (n=1). 
In addition, the UK and Germany have recorded NDM-1 
enzyme in Acinetobacter spp. (Table 1).
Among the 26 cases reported in European countries 
other than the UK, 14 were thought to be colonised 
with NDM-1-enzyme-producing organisms, whereas 12 
presented with infections affecting the urinary tract 
(n=6), skin and soft tissues (n=3), intra-abdominal cav-
ity (n=2), and lung (n=1). Among all 77 cases reported, 
including from the UK, four patients developed a 
bloodstream infection. Seven of the 77 patients died in 
hospital: In a 51-year old diabetic patient, death was 
attributed to septic shock from a necrotic leg wound 
infected with an NDM-1-positive E. coli. In another case 
the fatal outcome was unrelated to NDM-1. For the 
remaining five fatal cases, information on the cause of 
death was not available.
Thirty-eight of the 55 cases with a travel history had 
a link either to the Indian subcontinent (n=33) or to 
the Balkan region (n=5). Different temporal criteria 
were applied to travel history by the UK and the other 
survey participants to define this link. Among the 29 
cases in the UK, 17 had travelled to India or Pakistan 
in the year before detection of NDM-1. Among the 26 
cases from other EU countries, 22 had travelled in 
the month before diagnosis to a foreign country: 13 to 
India, three to Pakistan, two to Kosovo, two to Serbia, 
one to Montenegro and one to Bosnia and Herzegovina 
(Table 1).
Most patients with recent travel had been hospital-
ised in a foreign country during the 30 days prior to 
the detection of NDM-1 (Table 1). In the UK, 14 of 29 
patients had been admitted within the three years 
before detection of NDM-1 to a foreign hospital in 
India (n=8), Pakistan (n=4), India and Dubai (n=1) and 
Spain (n=1). In the other reporting countries, 18 of 26 
patients been admitted in the month before detection 
to a foreign hospital in India (n=10), the Balkans (n=5) 
or Pakistan (n=3) (Table 1). It appears that the major-
ity of these cases were admitted to foreign hospitals 
due to an illness or accident that occurred during the 
journey, although a minority were travelling for medi-
cal tourism.
Preliminary evidence suggests that 13 of 77 patients 
from Italy and the UK were possible secondary cases 
linked to other hospitalised patients who had returned 
from India (Table 1). In Italy, two cases with no travel 
history had stayed in a hospital unit to which a patient 
returning from India had previously been admitted. In 
the UK, 11 patients were involved in three clusters of 
possible cross-transmission. The hospital stay of two 
UK patients with no link to foreign countries over-
lapped with a travel-associated case. In another UK 
hospital, an endoscope-related outbreak affected nine 
patients six month after a travel-associated case. 
National guidance was available in 14 European coun-
tries in the form of online or peer-reviewed publications, 
addressing the management of Enterobacteriaceae pro-
ducing NDM-1 or other carbapenemases (Table 2). They 
all recommended clinical laboratory methods for resist-
ance detection and required that the resistance gene is 
confirmed by a reference laboratory. Cyprus and Latvia 
reported that reference microbiological methods were 
under development. It is of note that NDM-1 cases were 
reported in 10 of 14 countries with laboratory detec-
tion guidance, compared with three of 15 countries 
without such guidance (Tables 1 and 2). The majority 
of guidance documents also outlined the procedure for 
notification of health authorities and recommended 
infection control measures in healthcare facilities. 
Eight countries had a full set of guidance documents. 
Estonia, Ireland, and Slovakia indicated that such guid-
ance was in development. 
Guidance on control measures for patients with carbap-
enemase-producing Enterobacteriaceae was frequently 
part of broader recommendations on multidrug-resist-
ant microorganisms. Finland stated that such guid-
ance was under development in their country. Austria 
and Denmark indicated that infection control guide-
lines were developed by public health professionals at 
regional or hospital level. In France, guidance on the 
screening of patients transferred directly from foreign 
healthcare facilities was under revision to be extended 
to all patients exposed to such care facilities in the 
year preceding admission to a French hospital.
Discussion  
Incidence and geographical distribution 
Current data indicates an increase in the spread not only 
of NDM-1, but also of other carbapenemase-producing 
Enterobacteriaceae in Europe and worldwide [2-6]. We 
found here 77 NDM-1 cases in 13 countries in Europe 
over the last three years, with the majority of cases in 
the UK. It is likely that the number of cases reported is 
underestimated, because, in most countries, infections 
with highly-resistant Enterobacteriaceae are not notifi-
able, nor do they have to be laboratory-confirmed. 
Moreover, microbiological guidance on the detection 
and identification of acquired carbapenemases in 
Enterobacteriaceae is available in only a minority of 
European countries. These countries were more likely 
to identify cases. Cases have also been reported in 
2010 from Australia [18], Canada [19], Singapore [21], 
the US [10], and, according to recent media reports, 
from China, Israel, Japan, Kenya, Malaysia, Oman 
and Taiwan. The majority of cases described in our 
survey, as in other reports, had a history of recent 
travel and hospital admission on the Indian subcon-
tinent, but there was also a smaller proportion of 
cases who had received hospital care in Balkan coun-
tries. Further studies should determine the risk of 
healthcare-associated acquisition of NDM-1 and other 
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Country Number of patients Year of detection: first case/last case
NDM-1-producing bacterial 
species (number of isolates) Sex (male:female)
Age range 
(years)
Clinical presentation
Fatal cases Recent
a travel to country 
(number of cases)
Recenta healthcare in 
country  
(number of cases)
Possible 
secondary 
cases 
ReferenceCases of 
colonisation Cases of infection
Austria 3 2009/2010 Escherichia coli (1),Klebsiella pneumoniae (2) 3:0 14-56 1
Abdominal sepsis (1), 
Necrotising fasciitis (1) 0
India (1),
Kosovob (1),
Pakistan (1)
India (1),
Kosovob (1),
Pakistan (1)
0 [20]
Belgium 3 2010
E. coli (2),
K. pneumoniae (1),
Morganella morganii (1)
2:1 46-53 2 Sepsis from necrotic wound (1) 1
Kosovob and Serbia (1),
Montenegro (1),
Pakistan (1)
Kosovob and Serbia (1),
Montenegro (1),
Pakistan (1)
0 [25]
Bulgaria 0 NA NA NA NA NA NA NA NA NA NA
Cyprus 0 NA NA NA NA NA NA NA NA NA NA
Czech Republic 0 NA NA NA NA NA NA NA NA NA NA
Denmark 1 2010 K. pneumoniae (1) 0:1 57 1 NA 0  Bosnia and Herzegovina (1)
Bosnia and Herzegovina 
(1) 0 [23]
Estonia 0 NA NA NA NA NA NA NA NA NA NA
Finland 1 2010 K. pneumoniae (1) 1:0 46 1 NA 0 India (1) India (1) 0
France 4 2009/2010
Citrobacter freundii (1),
E. coli (1),
K. pneumoniae (1),
Proteus mirabilis (1)
2:2 18-63 2
Skin and soft tissue 
infection (1), Urinary tract 
infection (1)
0 India (4) India (3) 0 [26]
Germany 3c 2009/2010 E. coli (2),K. pneumoniae (1) 2:1 22-70 1 Urinary tract infection (2) NR
e India (1),
Pakistan (1)
India (1),
Pakistan (1) 0
Greece 0 NA NA NA NA NA NA NA NA NA NA
Hungary 0 NA NA NA NA NA NA NA NA NA NA
Iceland 0 NA NA NA NA NA NA NA NA NA NA
Ireland 0 NA NA NA NA NA NA NA NA NA NA
Italy 2 2009 E. coli (2) 2:0 NR 2 0 0 0 0 2d
Latvia 0 NA NA NA NA NA NA NA NA NA NA
Lithuania 0 NA NA NA NA NA NA NA NA NA NA
Luxembourg 0 NA NA NA NA NA NA NA NA NA NA
Malta 0 NA NA NA NA NA NA NA NA NA NA
Nether-lands 2 2008/2009 K. pneumoniae (2) 1:1 30-66 2 0 0 India (2) 0 0 [24]
Norway 2 2010 E. coli (1),K. pneumoniae (1) 1:1 65-70 1
Urinary tract infection and 
secondary bacteraemia (1) 0 India (1)
e India (1)e 0
Poland 0 NA NA NA NA NA NA NA NA NA NA
Portugal 0 NA NA NA NA NA NA NA NA NA NA
Romania 0 NA NA NA NA NA NA NA NA NA NA
Slovakia 0 NA NA NA NA NA NA NA NA NA NA
Slovenia 2 2009/2010 K.pneumoniae (2) 1:1 59-79 0 Pneumonia (1)Urinary tract infection (1) 0 Serbia (1) Serbia (1) 0
Spain 1 2010 K.pneumoniae (1) 1:0 36 0 Abdominal abscess (1) 0 India (1) India (1) 0
Sweden 2 2008/2010 E. coli (2),K. pneumoniae (1) 2:0 59-72 1 Urinary tract infection (1) 1 India (2) India (2) 0 [1]
United Kingdom (data 
set 1) 29
c 2008/2009
C. freundii (2),
Enterobacter spp.(4),
E. coli (5),
K. pneumoniae (17),
M. morganii (1)
15:13 2-87 NR NRf 5 NRg NRh 2i [2]
United Kingdom 
(data set 2) 22 2010 NR NR NR NR NR NR NR NR 9
lj
NA: not applicable; NR: data not reported 
a History of travel or contact with healthcare facilities in a foreign country within 30 days prior to NDM-1 detection.
b Under United Nations Security Council Resolution 1244.
c Additional cases of Acinetobacter baumannii with an NDM-1 enzyme: Germany (n=1), United Kingdom (n=9).
d Autochthonous cases staying at the same hospital unit at the same time as a patient who had previously travelled in India.
e The first case was admitted to a hospital in India with longer time interval (eight months) prior to NDM-1 detection.
f Specimen type: urine (n=19), wound (n=4), sputum (n=4), blood (n=3), other (n=7).
g Link to foreign country defined as  having travelled within the year  before NDM-1 detection in India or Pakistan or having been born there (n=17).
h Healthcare link to foreign country defined as having been admitted to hospital in the previous three years (n=14): India (n=8), Pakistan (n=4), India 
and Dubai (n=1) and Spain (n=1). 
i Two clusters, each comprising one index travel-associated case and one secondary case, who were both admitted to the same hospital unit during 
the same period.  
j Cluster of nine cases associated with a contaminated endoscope, caused by the same clonal type that had been found in a travel-associated case 
six months earlier.
Table 1
Demographic characteristics and travel history of patients colonised or infected with Enterobacteriaceae producing New 
Delhi metallo-beta-lactamase 1 in the European Union, Iceland and Norway, 2008-2010 (N=77)
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Country Number of patients Year of detection: first case/last case
NDM-1-producing bacterial 
species (number of isolates) Sex (male:female)
Age range 
(years)
Clinical presentation
Fatal cases Recent
a travel to country 
(number of cases)
Recenta healthcare in 
country  
(number of cases)
Possible 
secondary 
cases 
ReferenceCases of 
colonisation Cases of infection
Austria 3 2009/2010 Escherichia coli (1),Klebsiella pneumoniae (2) 3:0 14-56 1
Abdominal sepsis (1), 
Necrotising fasciitis (1) 0
India (1),
Kosovob (1),
Pakistan (1)
India (1),
Kosovob (1),
Pakistan (1)
0 [20]
Belgium 3 2010
E. coli (2),
K. pneumoniae (1),
Morganella morganii (1)
2:1 46-53 2 Sepsis from necrotic wound (1) 1
Kosovob and Serbia (1),
Montenegro (1),
Pakistan (1)
Kosovob and Serbia (1),
Montenegro (1),
Pakistan (1)
0 [25]
Bulgaria 0 NA NA NA NA NA NA NA NA NA NA
Cyprus 0 NA NA NA NA NA NA NA NA NA NA
Czech Republic 0 NA NA NA NA NA NA NA NA NA NA
Denmark 1 2010 K. pneumoniae (1) 0:1 57 1 NA 0  Bosnia and Herzegovina (1)
Bosnia and Herzegovina 
(1) 0 [23]
Estonia 0 NA NA NA NA NA NA NA NA NA NA
Finland 1 2010 K. pneumoniae (1) 1:0 46 1 NA 0 India (1) India (1) 0
France 4 2009/2010
Citrobacter freundii (1),
E. coli (1),
K. pneumoniae (1),
Proteus mirabilis (1)
2:2 18-63 2
Skin and soft tissue 
infection (1), Urinary tract 
infection (1)
0 India (4) India (3) 0 [26]
Germany 3c 2009/2010 E. coli (2),K. pneumoniae (1) 2:1 22-70 1 Urinary tract infection (2) NR
e India (1),
Pakistan (1)
India (1),
Pakistan (1) 0
Greece 0 NA NA NA NA NA NA NA NA NA NA
Hungary 0 NA NA NA NA NA NA NA NA NA NA
Iceland 0 NA NA NA NA NA NA NA NA NA NA
Ireland 0 NA NA NA NA NA NA NA NA NA NA
Italy 2 2009 E. coli (2) 2:0 NR 2 0 0 0 0 2d
Latvia 0 NA NA NA NA NA NA NA NA NA NA
Lithuania 0 NA NA NA NA NA NA NA NA NA NA
Luxembourg 0 NA NA NA NA NA NA NA NA NA NA
Malta 0 NA NA NA NA NA NA NA NA NA NA
Nether-lands 2 2008/2009 K. pneumoniae (2) 1:1 30-66 2 0 0 India (2) 0 0 [24]
Norway 2 2010 E. coli (1),K. pneumoniae (1) 1:1 65-70 1
Urinary tract infection and 
secondary bacteraemia (1) 0 India (1)
e India (1)e 0
Poland 0 NA NA NA NA NA NA NA NA NA NA
Portugal 0 NA NA NA NA NA NA NA NA NA NA
Romania 0 NA NA NA NA NA NA NA NA NA NA
Slovakia 0 NA NA NA NA NA NA NA NA NA NA
Slovenia 2 2009/2010 K.pneumoniae (2) 1:1 59-79 0 Pneumonia (1)Urinary tract infection (1) 0 Serbia (1) Serbia (1) 0
Spain 1 2010 K.pneumoniae (1) 1:0 36 0 Abdominal abscess (1) 0 India (1) India (1) 0
Sweden 2 2008/2010 E. coli (2),K. pneumoniae (1) 2:0 59-72 1 Urinary tract infection (1) 1 India (2) India (2) 0 [1]
United Kingdom (data 
set 1) 29
c 2008/2009
C. freundii (2),
Enterobacter spp.(4),
E. coli (5),
K. pneumoniae (17),
M. morganii (1)
15:13 2-87 NR NRf 5 NRg NRh 2i [2]
United Kingdom 
(data set 2) 22 2010 NR NR NR NR NR NR NR NR 9
lj
NA: not applicable; NR: data not reported 
a History of travel or contact with healthcare facilities in a foreign country within 30 days prior to NDM-1 detection.
b Under United Nations Security Council Resolution 1244.
c Additional cases of Acinetobacter baumannii with an NDM-1 enzyme: Germany (n=1), United Kingdom (n=9).
d Autochthonous cases staying at the same hospital unit at the same time as a patient who had previously travelled in India.
e The first case was admitted to a hospital in India with longer time interval (eight months) prior to NDM-1 detection.
f Specimen type: urine (n=19), wound (n=4), sputum (n=4), blood (n=3), other (n=7).
g Link to foreign country defined as  having travelled within the year  before NDM-1 detection in India or Pakistan or having been born there (n=17).
h Healthcare link to foreign country defined as having been admitted to hospital in the previous three years (n=14): India (n=8), Pakistan (n=4), India 
and Dubai (n=1) and Spain (n=1). 
i Two clusters, each comprising one index travel-associated case and one secondary case, who were both admitted to the same hospital unit during 
the same period.  
j Cluster of nine cases associated with a contaminated endoscope, caused by the same clonal type that had been found in a travel-associated case 
six months earlier.
6 www.eurosurveillance.org
Co
un
tr
y
Na
tio
na
l g
ui
da
nc
e 
on
 N
DM
-1
-p
ro
du
ci
ng
 o
r, 
m
or
e 
ge
ne
ra
lly
, c
ar
ba
pe
ne
m
as
e-
pr
od
uc
in
g 
En
te
ro
ba
ct
er
ia
ce
ae
Co
m
m
en
t
Re
fe
re
nc
e 
or
 U
RL
De
te
ct
io
n 
an
d 
su
rv
ei
lla
nc
e 
m
et
ho
ds
Re
fe
rr
al
 to
 re
fe
re
nc
e 
la
bo
ra
to
ry
N
ot
ifi
ca
tio
n 
to
 h
ea
lth
 
au
th
or
iti
es
In
fe
ct
io
n 
co
nt
ro
l 
m
ea
su
re
s
Au
st
ria
●
●
●
In
fe
ct
io
n 
co
nt
ro
l g
ui
de
lin
es
 a
t 
ho
sp
ita
l l
ev
el
ht
tp
:/
/w
w
w
.re
fe
re
nz
ze
nt
ru
m
.a
t 
Be
lg
iu
m
●
●
●
●
ht
tp
:/
/w
w
w
.n
si
h.
be
/s
ur
v_
ca
rb
a/
ca
rb
ap
en
em
as
e_
fr
.a
sp
 
ht
tp
:/
/w
w
w
.n
si
h.
be
/s
ur
v_
ca
rb
a/
ca
rb
ap
en
em
as
e_
nl
.a
sp
 
Cz
ec
h 
Re
pu
bl
ic
●
●
●
ht
tp
:/
/w
w
w
.s
zu
.c
z/
up
lo
ad
s/
do
cu
m
en
ts
/C
eM
/Z
pr
av
y_
EM
/1
8_
20
09
/3
_b
re
ze
n/
10
0_
be
ta
l.p
df
Fi
nl
an
d
●
●
In
fe
ct
io
n 
co
nt
ro
l g
ui
de
lin
es
 
un
de
r d
ev
el
op
m
en
t
ht
tp
:/
/w
w
w
.k
tl.
fi/
po
rt
al
/1
71
60
 
Fr
an
ce
●
●
●
●
In
fe
ct
io
n 
co
nt
ro
l g
ui
de
lin
es
 
un
de
r r
ev
is
io
n
ht
tp
:/
/w
w
w
.h
cs
p.
fr/
ex
pl
or
e.
cg
i/
hc
sp
r2
01
00
51
8_
bm
rim
po
rt
ee
s.
pd
f 
Ge
rm
an
y
●
●
●
ht
tp
:/
/w
w
w
.r
ki
.d
e/
cl
n_
16
9/
nn
_2
05
76
0/
DE
/C
on
te
nt
/I
nf
ek
t/
Kr
an
ke
nh
au
sh
yg
ie
ne
/E
rr
eg
er
__
au
sg
ew
ae
hl
t/
ES
BL
/E
SB
L_
_
LI
T_
_0
3,
te
m
pl
at
eI
d=
ra
w
,p
ro
pe
rt
y=
pu
bl
ic
at
io
nF
ile
.p
df
/
ES
BL
_L
IT
_0
3.
pd
f
Gr
ee
ce
●
●
●
●
ht
tp
:/
/w
w
w
.k
ee
lp
no
.g
r/
im
ag
es
/s
to
rie
s/
ke
el
pn
o/
pr
ok
ro
us
tis
/p
ro
kr
ou
st
is
20
10
.d
oc
 
Ne
th
er
la
nd
s
●
●
●
●
[3
1,
33
]
No
rw
ay
●
●
●
ht
tp
:/
/w
w
w
.u
nn
.n
o/
k-
re
s/
m
et
od
er
-fo
r-
pa
av
is
ni
ng
-
av
-k
ar
ba
pe
ne
m
as
e-
pr
od
us
er
en
de
-e
sb
l-c
ar
ba
-
en
te
ro
ba
ct
er
ia
ce
ae
-a
rt
ic
le
77
54
6-
21
58
8.
ht
m
l 
ht
tp
:/
/w
w
w
.fh
i.n
o/
do
ku
m
en
te
r/
96
33
11
78
b9
.p
df
 
Po
la
nd
●
●
●
●
ht
tp
:/
/w
w
w
.a
nt
yb
io
ty
ki
.e
du
.p
l 
ht
tp
:/
/w
w
w
.k
or
ld
.e
du
.p
l 
Po
rt
ug
al
●
●
●
●
O
rie
nt
aç
ão
 n
º 
00
6/
20
10
 d
e 
04
/1
0/
20
10
 (A
va
ila
bl
e 
at
: h
tt
p:
//
w
w
w
.d
gs
.p
t)
Sl
ov
en
ia
●
●
●
ht
tp
:/
/w
w
w
.m
z.
go
v.
si
/f
ile
ad
m
in
/m
z.
go
v.
si
/p
ag
eu
pl
oa
ds
/
m
z_
do
ku
m
en
ti/
de
lo
vn
a_
po
dr
oc
ja
/z
dr
av
st
ve
no
_v
ar
st
vo
/
zd
ra
vs
tv
en
o_
va
rs
tv
o_
v_
po
se
bn
ih
/N
AK
O
BO
_o
kt
ob
er
_2
01
0/
PR
IP
O
RO
CI
LA
_E
SB
L_
18
.1
0.
20
10
.d
oc
Sw
ed
en
●
●
●
●
ht
tp
:/
/s
oa
pi
m
g.
ic
ec
ub
e.
sn
ow
fa
ll.
se
/s
tr
am
a/
ES
BL
do
ku
m
en
t%
20
in
kl
%
20
ba
kg
ru
nd
.p
df
ht
tp
:/
/s
oa
pi
m
g.
ic
ec
ub
e.
sn
ow
fa
ll.
se
/s
tr
am
a/
su
pp
le
m
en
t%
20
2%
20
ES
BL
%
20
de
fin
iti
on
.p
df
Un
ite
d 
Ki
ng
do
m
●
●
●
●
ht
tp
:/
/w
w
w
.h
pa
.o
rg
.u
k/
w
eb
/H
PA
w
eb
Fi
le
/
HP
Aw
eb
_C
/1
24
88
54
04
64
70
 
ht
tp
:/
/w
w
w
.h
pa
.o
rg
.u
k/
w
eb
/H
PA
w
eb
Fi
le
/
HP
Aw
eb
_C
/1
24
88
54
04
54
73
 
ND
M
-1
: N
ew
 D
el
hi
 m
et
al
lo
-b
et
a-
la
ct
am
as
e-
1.
Ta
bl
e 
2
Av
ai
la
bl
e 
na
tio
na
l g
ui
da
nc
e 
do
cu
m
en
ts
 o
n 
th
e 
m
an
ag
em
en
t o
f c
ar
ba
pe
ne
m
as
e-
pr
od
uc
in
g 
En
te
ro
ba
ct
er
ia
ce
ae
, i
n 
14
 E
ur
op
ea
n 
co
un
tr
ie
s, 
as
 o
f 7
 O
ct
ob
er
 2
01
0
7www.eurosurveillance.org
carbapenemase-producing Enterobacteriaceae in dif-
ferent parts of the world.
Laboratory detection and identification
Carbapenem resistance mediated by NDM-1 enzyme 
has been detected by clinical laboratories with routine 
phenotypic testing methods, including disc diffusion 
testing [1,2,10,11,18-26]. Any Enterobacteriaceae iso-
late that exhibits a minimum inhibitory concentration 
(MIC) above the epidemiological cut-off or with clini-
cal resistance to ertapenem, imipenem or meropenem 
should trigger further testing [12,27] Carbapenemase 
activity can be screened by using the modified Hodge 
test [2,10-12] and, as with other metallo-beta-lactama-
ses, synergy can be detected by EDTA-imipenem disc 
or Etest [1,2,10-12,]. Widely used automated suscepti-
bility systems show good sensitivity but poor specifi-
city for detection of carbapenem resistance mediated 
by NDM-1 and other carbapenemases [13]. Further 
evaluation of in-house and commercial test systems 
with larger numbers of NDM-1-producing strains are 
desirable, given the variable phenotypic expression of 
carbapenemase activity, as observed with strains pro-
ducing KPC- and VIM-like enzymes [3,6,11,14,15,27]. 
Confirmation of the NDM-1 enzyme requires molecular 
analysis, typically PCR or DNA sequencing, by a ref-
erence laboratory [1,2,7,11]. A limitation of our study 
was the absence of a molecular case definition or a 
description of molecular NDM-1 identification meth-
ods. However, 38 of 77 cases described here have been 
published elsewhere with details of molecular identifi-
cation (Table 1) and the majority of the remainder were 
reported by the same expert laboratories according to 
published national standards (Table 2). 
Epidemic risk assessment
What is the epidemic potential of NDM-1? The blaNDM-1 
determinant was located on conjugative plasmids 
in the majority of the producer E. coli and K. pneu-
moniae clinical isolates [2]. In a few isolates, blaNDM-1 
was located on the bacterial chromosome, indicating 
intragenomic recombination [2]. NDM-1 was produced 
both by a K. pneumoniae isolate from urine and a fae-
cal E. coli isolate from the same patient, suggesting in 
vivo transfer [1]. These characteristics indicate a potent 
capacity for horizontal dissemination, as further evi-
denced by detection of blaNDM-1 in multiple genera of 
Enterobacteriaceae and in A. baumannii [2,11].
Many NDM-1 cases had co-morbidities and/or had 
undergone an invasive care procedure [1,2,19-26]. The 
clinical spectrum and severity of illness appears simi-
lar to that expected for Enterobacteriaceae infections in 
this patient population. There is a paucity of informa-
tion on the extent and mode of transmission of NDM-1-
producing bacteria in the community and in healthcare 
settings. By analogy with the epidemiology of the 
bacterial host, indirect faecal-oral inter-human trans-
mission is likely to play a major role, via contaminated 
hands, food or water, particularly in countries with lim-
ited access to adequate sanitary infrastructure. In India, 
the majority of NDM-1-producing Enterobacteriaceae 
were community-acquired [2,7]. In the present survey, 
travel-associated cases who had had no contact with 
healthcare systems presumably acquired NDM-1 in the 
community [16,24]. 
Control interventions
Screening of colonisation with multidrug-resistant 
organisms upon admission to hospitals has been 
advocated in patients who have received healthcare 
in endemic countries or epidemic facilities [28-31]. 
Further interventions include preemptive isolation of 
these patients in single bedrooms and barrier precau-
tions for the period while the screening results are 
pending, and continued for colonised patients [28-31]. 
So far, evidence of secondary nosocomial transmission 
of bacteria with the NDM-1 enzyme in Europe is lim-
ited, possibly as the result of such proactive infection 
control measures. Evidence-based control measures 
should be identified for all carbapenemase-positive 
bacteria and implemented in patient care.
Public health response
Public health preparedness for the control of carbap-
enemase-producing Enterobacteriaceae, including 
those producing NDM-1 enzyme, is progressing across 
Europe as evidenced by our survey (Table 2). Key com-
ponents of current public health practices include (i) 
dissemination of national guidelines for microbiologi-
cal laboratory detection, and (ii) recommendations for 
active surveillance and additional infection control pre-
cautions for patients who have received cross-border 
healthcare. Laboratory and epidemiological support 
should be readily available for the investigation of 
imported or indigenous cases and for the control of 
secondary transmission. Recent experiences with large 
epidemics of KPC and VIM carbapenemase-producing 
Enterobacteriaceae associated with significant mortal-
ity in the US, Greece and Israel, have highlighted the 
need for strengthening public health and the response 
capacity of healthcare systems, notably by dedicated 
national task forces and public health laboratory net-
works [28-30]. Member States could also consider pro-
viding information to their citizens seeking healthcare 
in foreign countries about the risk of acquiring NDM-1 
and other extensively antibiotic-resistant bacterial 
pathogens.
EU-wide surveillance should be strengthened to 
enable monitoring of extensively  antibiotic-resist-
ant pathogens such as carbapenemase-producing 
Enterobacteriaceae. Linking national reference labora-
tories and public health institutes through antimicrobial 
resistance surveillance networks such as the EARS-Net, 
implementing national generic communicable diseases 
reporting and early warning systems to ensure rapid 
communication and a timely response, could be further 
studied as best practice to be shared among countries 
for effective containment of these extensively resistant 
pathogens. At the EU level, rapid information exchange 
by means of electronic communication platforms such 
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as the Epidemic Intelligence System (EPIS) [32] or the 
Early Warning and Response System (EWRS) would 
result in an integrated European approach.
European NDM-1 Survey Participants:
Austria - A. Grisold, G. Zarfel; Belgium - B. Jans; Bulgaria - T. 
Velinov, T. Kantardjiev; Cyprus - M. Alexandrou; Czech Republic 
- H. Zemlickova, J. Hrabak; Denmark - N. Frimodt-Møller, A.M. 
Hammerum; Estonia - M. Maimets, M. Ivanova; Finland - J. Jalava, 
M. Rummukainen; France - RAISIN (French Healthcare-Associated 
Infection Alert, Investigation and Surveillance Network); Germany 
- T. Eckmanns, M. Kaase; Greece - X. Dedoukou, A. Vatopoulos; 
Hungary - K. Böröcz; Iceland - K.G. Kristinsson, O. Gudlaugsson; 
Ireland - R. Cunney; Italy - G.M. Rossolini, A. Pantosti; Latvia - 
U. Dumpis, A. Balode; Lithuania - R. Valinteliene; Luxembourg 
- P. Weicherding; Malta - M. Borg; Netherlands -M.A. Leverstein-
van Hall, X. Huijsdens; Norway - Ø. Samuelsen, G.S. Simonsen; 
Poland - W. Hryniewicz, M. Gniadkowski; Portugal - A.C. Costa, 
M. Caniça; Romania - I. Codita, R. Serban; Slovakia - L. Siegfried, 
M. Stefkovicova; Slovenia - J. Kolman, M. Pirš; Spain - J. Oteo, J. 
Campos; Sweden - K. Tegmark-Wisell, P. Edquist; United Kingdom - 
D. Livermore, N. Woodford 
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